GlassScriptPhysician profile
Mark P Tallman
NPI 1174518989
$27,596.48
in general payments reported to CMS, 2019-2025
9 companies · $495 in 2025
The $495 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $615 · 2021: $4,581 · 2022: $2,009 · 2023: $387 · 2024: $1,280 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17,277.01 | 2019 | |
| Abbott Laboratories | $9,640.94 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console, Cardiomems |
| Elutia, INC. | $361.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.95 | 2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $65.81 | 2020 | |
| United Therapeutics Corporation | $45.00 | 2019 | |
| Cvrx, INC. | $44.00 | 2023 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $31.66 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $18.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tallman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.